Impact Highlights

→ Leadership team trust increased from 2.3 to 4.4 (Lencioni scale)
→ Constructive conflict strengthened from 2.9 to 4.0
→ Commitment, accountability and results moved into the high-performance range
→ Leadership cohesion improved across multiple organisational layers
→ Successful transition from R&D-led biotech to commercial biopharma in a high-value global market

‍

From Science to Market

After more than two decades as a research-driven biotechnology company, this late-stage biopharma organisation was approaching a defining moment – preparing to bring its first major therapy to market.

The therapy addressed a serious and underserved condition affecting a significant global patient population, with the potential to shift treatment beyond symptom management.

Internally, however, the organisation was still shaped by its R&D heritage. For 25+ years it had been built around scientific discovery and patient purpose. As commercialisation approached, a new commercial organisation was being built almost from scratch.

The context added complexity. Previous regulatory challenges had created uncertainty and raised questions about the organisation’s readiness to transition successfully. At the same time, the newly formed commercial leadership team brought together individuals from very different backgrounds – experienced pharmaceutical leaders alongside long-standing R&D leaders.

The result was a group with strong expertise but limited cohesion.

Trust was fragile. Collaboration was inconsistent. Leadership behaviours had not yet aligned with the realities of commercial execution. A newly appointed Head of Commercial recognised that success would depend on more than strategy. It required a leadership team capable of operating as a cohesive system under pressure.

‍

Stabilising the Leadership Core

The work began with the Commercial Leadership Team. Initial diagnostics, including the Lencioni Team Assessment, confirmed a pattern often seen in organisations transitioning from research to commercial execution. Scores across the five behaviours of high-performing teams were in the low to medium range, with particularly low levels of trust and constructive conflict.

Leaders were cautious about challenging one another. Difficult issues were left unspoken. Debate was limited, slowing alignment and decision-making.

Without trust, constructive conflict does not happen. Without conflict, commitment and accountability remain weak. Through a combination of deep diagnostics, facilitated leadership sessions and executive coaching, these dynamics were surfaced directly.

Leaders developed a shared language to address behaviours that had previously remained unspoken. Trust began to build. Conversations that had been avoided became possible.

By the end of this phase, the Commercial Leadership Team had stabilised as an intact group capable of working through disagreement and aligning around decisions.

‍

Building Leadership Depth

The work then expanded to the Senior Director population – the leaders responsible for translating strategy into action.

Capability at this level was strong, but there remained an undercurrent of scepticism following earlier setbacks.

A pivotal moment came when the Head of Commercial shared a personal perspective on the therapy and its importance for patients. This shifted the conversation. Leaders reconnected with purpose and the focus moved beyond strategy and structure to belief, mindset and behaviour.

Launch readiness was reframed. It was not only about capability – it was about cohesion, alignment and how leaders respond under pressure.

‍

Creating One Leadership System

Rather than developing leadership groups in isolation, the next phase brought the Commercial Leadership Team and Senior Directors together. The focus was to operate as one leadership system.

Facilitated dialogue enabled leaders to surface tensions between organisational layers – common in high-pressure environments where silos, ownership boundaries and competing priorities emerge. These dynamics were addressed directly.

As trust strengthened, leaders became more confident challenging assumptions, raising issues earlier and resolving tensions without escalation. The organisation began to move from a collection of capable individuals to a coherent leadership team.

‍

Extending Alignment Across the Organisation

As launch preparation intensified, the work extended further:

→ The Corporate Steering Committee explored enterprise-level leadership dynamics, including governance and decision-making
→ A broader Senior Leadership Team session aligned around shared narrative and future direction
→ Regional and functional teams, including commercial and supply chain leadership, were engaged to strengthen cohesion

In multiple areas, teams moved rapidly from fragmented collaboration to aligned, high-functioning leadership groups.

‍

The Outcome

Over the course of the engagement, the leadership team evolved from a group navigating uncertainty into a cohesive system able to debate, decide and act together.

Just as importantly, belief in the organisation’s mission strengthened. As leaders reconnected with the patient impact of their work, the conversation shifted from caution to commitment.

This alignment proved critical as the organisation approached a defining milestone, marking its transition from a research-led biotech to a commercial biopharmaceutical company.

‍

‍

Why Leadership Mindset and Behaviour Matter

Major therapy launches place sustained pressure on leadership teams. Alignment, speed of decision-making and cross-functional trust directly affect execution. By strengthening mindset, trust and accountability, this organisation built a leadership culture capable of operating under pressure and delivering at a critical moment.

As launch reality sets in, the challenge is not maintaining effort. It is sustaining repeatable operational excellence, enabling decisions with incomplete information and trusting teams without reverting to micromanagement.

The organisation continues to partner with Open Water, focusing on strengthening leadership across key operational areas like Global Supply Chain and Technology.

The priority remains unchanged – trust, clarity and alignment to keep patient-centred outcomes moving under pressure.

‍